Literature DB >> 17254640

Disruption of the beta2-integrin CD11d (alphaDbeta2) gene fails to protect against experimental autoimmune encephalomyelitis.

Jillian E Adams1, Matthew S Webb, Xianchen Hu, Don Staunton, Scott R Barnum.   

Abstract

The fourth member of the beta(2)-integrin family of adhesion molecules, CD11d (alpha(D)beta(2)), is expressed on a wide variety of immune cells, however its function in autoimmune diseases, including EAE remains unknown. We induced EAE in wild-type and CD11d(-/-) C57BL/6 mice using myelin oligodendrocyte glycoprotein (MOG(35-55)) peptide. The clinical course and histopathology of EAE were identical in both groups of mice throughout the disease course. There were no significant differences in the infiltration of leukocyte subsets into the central nervous system or in the production of cytokines from T cells isolated from the spleen or spinal cord from both groups of mice. Our data demonstrate that CD11d is not required for the development of EAE and, to date, is the only beta(2)-integrin molecule whose deletion does not result in attenuated disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17254640      PMCID: PMC2747331          DOI: 10.1016/j.jneuroim.2006.12.007

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  37 in total

Review 1.  P marks the spot: site-specific integrin phosphorylation regulates molecular interactions.

Authors:  Susanna C Fagerholm; Tiina J Hilden; Carl G Gahmberg
Journal:  Trends Biochem Sci       Date:  2004-09       Impact factor: 13.807

2.  Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

Authors:  T A Yednock; C Cannon; L C Fritz; F Sanchez-Madrid; L Steinman; N Karin
Journal:  Nature       Date:  1992-03-05       Impact factor: 49.962

3.  Transient blockade of the CD11d/CD18 integrin reduces secondary damage after spinal cord injury, improving sensory, autonomic, and motor function.

Authors:  Denis Gris; Daniel R Marsh; Mark A Oatway; Yuhua Chen; Eilis F Hamilton; Gregory A Dekaban; Lynne C Weaver
Journal:  J Neurosci       Date:  2004-04-21       Impact factor: 6.167

4.  Anti-macrophage CR3 antibody blocks myelin phagocytosis by macrophages in vitro.

Authors:  W Brück; R L Friede
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

5.  Augmentation of adoptively transferred experimental allergic encephalomyelitis by administration of a monoclonal antibody specific for LFA-1 alpha.

Authors:  C T Welsh; J W Rose; K E Hill; J J Townsend
Journal:  J Neuroimmunol       Date:  1993-03       Impact factor: 3.478

6.  An anti-CD11d integrin antibody reduces cyclooxygenase-2 expression and protein and DNA oxidation after spinal cord injury in rats.

Authors:  Feng Bao; Yuhua Chen; Gregory A Dekaban; Lynne C Weaver
Journal:  J Neurochem       Date:  2004-09       Impact factor: 5.372

7.  A monoclonal antibody to CD11d reduces the inflammatory infiltrate into the injured spinal cord: a potential neuroprotective treatment.

Authors:  L R Saville; C H Pospisil; L A Mawhinney; F Bao; F C Simedrea; A A Peters; P J O'Connell; L C Weaver; G A Dekaban
Journal:  J Neuroimmunol       Date:  2004-11       Impact factor: 3.478

8.  Treatment with anti-CR3 antibodies ED7 and ED8 suppresses experimental allergic encephalomyelitis in Lewis rats.

Authors:  I Huitinga; J G Damoiseaux; E A Döpp; C D Dijkstra
Journal:  Eur J Immunol       Date:  1993-03       Impact factor: 5.532

9.  Tumor necrosis factor-induced degranulation in adherent human neutrophils is dependent on CD11b/CD18-integrin-triggered oscillations of cytosolic free Ca2+.

Authors:  J Richter; J Ng-Sikorski; I Olsson; T Andersson
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

10.  A controlled trial of natalizumab for relapsing multiple sclerosis.

Authors:  David H Miller; Omar A Khan; William A Sheremata; Lance D Blumhardt; George P A Rice; Michele A Libonati; Allison J Willmer-Hulme; Catherine M Dalton; Katherine A Miszkiel; Paul W O'Connor
Journal:  N Engl J Med       Date:  2003-01-02       Impact factor: 91.245

View more
  4 in total

Review 1.  beta2-integrins in demyelinating disease: not adhering to the paradigm.

Authors:  Xianzhen Hu; Jillian E Wohler; Kari J Dugger; Scott R Barnum
Journal:  J Leukoc Biol       Date:  2009-12-09       Impact factor: 4.962

2.  Deletion of the G2A receptor fails to attenuate experimental autoimmune encephalomyelitis.

Authors:  Inga Osmers; Sherry S Smith; Brian W Parks; Shaohua Yu; Roshni Srivastava; Jillian E Wohler; Scott R Barnum; Janusz H S Kabarowski
Journal:  J Neuroimmunol       Date:  2009-01-09       Impact factor: 3.478

3.  p150/95 (CD11c/CD18) expression is required for the development of experimental autoimmune encephalomyelitis.

Authors:  Daniel C Bullard; Xianzhen Hu; Jillian E Adams; Trenton R Schoeb; Scott R Barnum
Journal:  Am J Pathol       Date:  2007-06       Impact factor: 4.307

Review 4.  β2 Integrin CD11d/CD18: From Expression to an Emerging Role in Staged Leukocyte Migration.

Authors:  Eoin N Blythe; Lynne C Weaver; Arthur Brown; Gregory A Dekaban
Journal:  Front Immunol       Date:  2021-11-08       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.